Clinical Characteristics and Inflammatory Immune Responses in COVID-19 Patients With Hypertension: A Retrospective Study
Pharmacology
[키워드] 95% CI
ACEi
addition
administration
affecting
alleviate
angiotensin receptor blocker
angiotensin-converting enzyme inhibitor
antihypertensive agent
ARB
association
AST
Biomarker
blood pressure
CD4
CD8
clinical
Clinical characteristics
condition
COVID-19
COVID-19 patient
COVID-19 patients
CRP
disease
examined
group
groups
high mortality
high risk
higher risk
hypertension
hypertensive patient
immune
Inflammatory
inflammatory immune response
inflammatory immune responses
Injury
LDL-C
Low-Density Lipoprotein cholesterol
metabolic disorder
myocardial injury
neutrophil count
organ damage
oxygen uptake
Patient
PCT
Prognosis
RAAS blockers
response
severity of COVID-19
significantly lower
statistical significance
statistically
subgroup
white cell
with COVID-19
[DOI] 10.3389/fphar.2021.721769 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2021.721769 PMC 바로가기 [Article Type] Pharmacology